Apeiron Investment Group Ltd., 10% Owner, Director at ATAI Life Sciences N.V. (ATAI), bought 1,800,000 shares at $1.40 ($2.5M) on 2025-03-24, disclosed to the SEC on 2025-03-24.
Open-market purchase of $2.5M ATAI by 10% Owner, Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Nothing distinguishes this filing.
| Filing → |
| ENHA | BUY | 2026-09-04 | $210K | — | Filing → |
| ENHA | BUY | 2026-08-20 | $2.9M | — | Filing → |
| ENHA | BUY | 2026-08-18 | $330K | — | Filing → |